<DOC>
	<DOCNO>NCT01913990</DOCNO>
	<brief_summary>For breast cancer patient receive chemotherapy regimen , use validate emesis ( nausea vomit ) risk calculator provide superior anti-emetic ( nausea vomit ) control compare `` standard '' anti-emetic regimen . The risk calculator potential provide individualize anti-emetic regimen decrease use toxic/costly anti-emetics patient low risk possibly importantly enhance appropriate anti-emetic regimen patient high risk .</brief_summary>
	<brief_title>Prevention Chemotherapy Induced Nausea Vomiting Breast Cancer Patients .</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Newly diagnose invasive breast cancer ( stage IIII ) Scheduled receive neoadjuvant adjuvant intravenous anthracycline cyclophosphamidebased chemotherapy ; Able consent fill study form Received previous chemotherapy Symptoms nausea vomit baseline ( disease relate ) On chronic antiemetic therapy On daily corticosteroid prior initiation chemotherapy Allergic steroid , 5HT3 NK1 Uncontrolled diabetes Medical psychiatric illness would interfere patient ' ability complete diary</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>